They offer a 90 day supply of Actimmune at a reduced cost to those who are eligible for the program. The therapy is currently not approved for this indication top line results from a Phase III trials assessing its safety and efficacy in this patient population are expected by the end of the year. Actimmune Patient Assistance Program is provided by InterMune, Inc. In a separate agreement, Horizon has also snapped up US, European and Canadian intellectual property rights for interferon gamma-1b for the treatment of Friedreich's ataxia from an undisclosed their party. The transaction is expected to close by year-end 2016, subject to the satisfaction of closing conditions. Under the terms of the deal, Horizon has paid Boehringer 5 million euros upon signing and will pay 20 million euros upon closing for the rights for interferon gamma-1b in all territories outside of the US, Canada and Japan.
#Actimmune interferon gamma copay assistance program free
In the US the drug is marketed under the trade name Actimmune, and is approved for reducing the frequency and severity of serious infections linked to chronic granulomatous disease and for extending progression free survival in patients with severe, malignant osteopetrosis. The move will leave the firm with global rights to the drug - a biologically manufactured protein similar to one the body makes naturally to help prevent infection - as it already owns those for the rest of the world. Dublin-Ireland based biopharma Horizon Pharma has bagged rights to Boehringer Ingelheim's interferon gamma-1b in an around 30 countries primarily in Europe and the Middle East for 25 million euros.
0 kommentar(er)
